SGEN *

Seagen BMV:SGEN * Stock Report

Last Price

Mex$2.99k

Market Cap

Mex$486.0b

7D

0%

1Y

n/a

Updated

05 Feb, 2023

Data

Company Financials +

SGEN * Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

SGEN * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$2,994.97
52 Week HighUS$2,994.97
52 Week LowUS$2,994.97
Beta0.57
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-22.98%

Recent News & Updates

Recent updates

Shareholder Returns

SGEN *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how SGEN * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how SGEN * performed against the MX Market.

Price Volatility

Is SGEN *'s price volatile compared to industry and market?
SGEN * volatility
SGEN * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: Insufficient data to determine SGEN *'s volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine SGEN *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,675David Epsteinhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
SGEN * fundamental statistics
Market CapMex$486.02b
Earnings (TTM)-Mex$12.08b
Revenue (TTM)Mex$35.36b

13.7x

P/S Ratio

-40.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SGEN * income statement (TTM)
RevenueUS$1.86b
Cost of RevenueUS$1.68b
Gross ProfitUS$184.76m
Other ExpensesUS$821.53m
Earnings-US$636.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 15, 2023

Earnings per share (EPS)-3.43
Gross Margin9.91%
Net Profit Margin-34.16%
Debt/Equity Ratio0%

How did SGEN * perform over the long term?

See historical performance and comparison